• ホーム
  • 検索結果
  • Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong.

Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong.

The Journal of infectious diseases (1999-12-23)
C Buxton Bridges, J M Katz, W H Seto, P K Chan, D Tsang, W Ho, K H Mak, W Lim, J S Tam, M Clarke, S G Williams, A W Mounts, J S Bresee, L A Conn, T Rowe, J Hu-Primmer, R A Abernathy, X Lu, N J Cox, K Fukuda
要旨

The first outbreak of avian influenza A (H5N1) occurred among humans in Hong Kong in 1997. To estimate the risk of person-to-person transmission, a retrospective cohort study was conducted to compare the prevalence of H5N1 antibody among health care workers (HCWs) exposed to H5N1 case-patients with the prevalence among nonexposed HCWs. Information on H5N1 case-patient and poultry exposures and blood samples for H5N1-specific antibody testing were collected. Eight (3.7%) of 217 exposed and 2 (0.7%) of 309 nonexposed HCWs were H5N1 seropositive (P=.01). The difference remained significant after controlling for poultry exposure (P=.01). This study presents the first epidemiologic evidence that H5N1 viruses were transmitted from patients to HCWs. Human-to-human transmission of avian influenza may increase the chances for the emergence of a novel influenza virus with pandemic potential.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Monoclonal Anti-HEMAGGLUTININ antibody produced in mouse, clone 4F1F2, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-HEMAGGLUTININ antibody produced in mouse, clone 1E6A7, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-HEMAGGLUTININ antibody produced in mouse, clone 7B9B2, affinity isolated antibody
Sigma-Aldrich
Anti-AVIAN INFLUENZA NEURAMINIDASE antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-AVIAN INFLUENZA A M2 antibody produced in rabbit, affinity isolated antibody

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。